Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
Currently tolerating treatment in the parent protocol.
Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
Have at least stable disease, as determined by the investigator.
Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
You may not be if
Has been permanently discontinued from study treatment in the parent study for any reason.
Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.
Clareo Health | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
